Navigation Links
China-Biotics, Inc. Appoints New Chief Financial Officer

SHANGHAI, March 6 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced Lewis Fan will succeed Raymond Li as Chief Financial Officer, effective March 6, 2009. Mr. Li will continue to serve as Vice President of Finance to the Company.

Reporting to Mr. Jinan Song, Chairman and Chief Executive Officer, Mr. Fan will be responsible for all aspects of China-Biotics' finance functions, including accounting, financial planning, tax, treasury and audit. Prior to joining China-Biotics, Mr. Fan was Vice President and Senior Equity Analyst for Brean Murray, Carret & Co., where he covered the Chinese healthcare industry. He previously served as an equity analyst at UBS and as an emerging markets strategist at Deutsche Bank.

"I want to thank Raymond for his dedicated contributions as our Chief Financial Officer. He steered this company through its first public financing and has been chiefly responsible for our transition last year to the Nasdaq Global Market. We look forward to his continuing input and experience," said Mr. Song. "We are also excited to welcome Lewis as our new CFO. His combined technical knowledge in both finance and science will be an ideal fit as we move into the next phase of our life as a public company."

Prior to his Wall Street career, Mr. Fan served as a research scientist focusing on natural product drug discovery at Schering-Plough. He holds a Master of Business Administration degree in finance from New York University, a Master of Science degree in medicinal chemistry from the University of Michigan and a Bachelor of Arts degree with honors in biology and chemistry from Luther College.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    For more information, please contact:

     CCG Investor Relations
     Crocker Coulson, President
     Phone: +1-646-213-1915 (New York)

SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
2. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
3. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
4. China-Biotics, Inc. Retains KPMG for the Implementation of Sarbanes-Oxley Act Section 404
5. China-Biotics, Inc. Approved to List on the Nasdaq Global Market
6. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
7. China-Biotics, Inc. Provides Update on Construction of New Manufacturing Facility
8. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
9. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. China-Biotics, Inc. Files Application for Nasdaq Listing
Post Your Comments:
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):